Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Glucocorticoid Inflammation Paradox in Human Skeletal Muscle

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03529929
Recruitment Status : Withdrawn (withdrawn)
First Posted : May 18, 2018
Last Update Posted : March 11, 2020
Sponsor:
Information provided by (Responsible Party):
Melinda Sheffield-Moore, Texas A&M University

Brief Summary:
In this project, we propose to investigate the metabolic consequences of glucocorticoid therapy, given orally as a 6 day Medrol Dose pack, on human skeletal muscle as measured by western blotting and PCR and skeletal muscle mitochondrial capacity as measured by High-Resolution Respirometry in healthy individuals. Medrol is an FDA approved drug with many clinical indications.

Condition or disease Intervention/treatment Phase
Aging Drug: Methylprednisolone Phase 3

Detailed Description:

Healthy male and female individuals ages 60 - 80 (n=10) will be studied before and after 6 days of treatment with self-administered daily oral methylprednisolone.

Subjects will report to the Texas A&M Human Clinical Research Facility (HCRF) for testing before (day 0) and after (day 6) methylprednisolone intervention. Each visit will consist of determination of lean and fat mass using DEXA and a single muscle biopsy. Blood will be collected (up to 15ml) at screening, baseline and the conclusion of the study to measure metabolites and hormones. Phone calls will be made to subjects mid-week (day 3) during the study period to ensure compliance and continued consent.

This will be an unblinded study. All participants will receive methylprednisolone treatment.

Therapeutic Interventions. Methylprednisolone (Medrol®) dose pack. Methylprednisolone is a glucocorticoid. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract. Therapeutic methylprednisolone is approved for clinical use for a variety of disorders. Medrol®, the agent to be used in this study, is manufactured by Pfizer.

Medrol® is supplied as white tablets, of 4mg each. The tablets come in a commercially produced blister pack with instructions for each day of the 6 day dosing on the packaging. Subjects will receive a standard 6-day, graded dosing regimen of methylprednisolone (24mg, 20mg, 16mg, 12mg, 8mg, and 4 mg on days 1 through 6 respectively, Table 1 above). This methylprednisolone dosing regimen is commonly prescribed for the treatment of inflammation associated with a number of pathologies, including arthritic, respiratory, and neoplastic diseases. The Medrol® pack has clear instructions on how to administer the tablets and participants will be given additional instruction to ensure understanding for proper self-administration.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Glucocorticoid Inflammation Paradox in Human Skeletal Muscle
Estimated Study Start Date : June 1, 2019
Estimated Primary Completion Date : May 1, 2020
Estimated Study Completion Date : December 1, 2020


Arm Intervention/treatment
Experimental: Methylprednisolone

Methylprednisolone glucocorticoid Medrol Dose Pack

Medrol is supplied as white tablets, of 4mg each. The tablets come in a commercially produced blister pack with instructions for each day of the 6 day dosing on the packaging. Subjects will receive a standard 6-day, graded dosing regimen of methylprednisolone (24mg, 20mg, 16mg, 12mg, 8mg, and 4 mg on days 1 through 6 respectively).

Drug: Methylprednisolone
6 day dosing as dictated by Medrol 6 Day Dose Pack
Other Names:
  • Medrol Dose Pack
  • Medrol




Primary Outcome Measures :
  1. Oxidative Phosphorylation Capacity measured by high resolution tissue respirometry on day 0 [ Time Frame: day 0 ]
    Oxidative Phosphorylation will be measured in muscle tissue using high resolution respirometry (Oroboros O2K) on day 0.

  2. Oxidative Phosphorylation Capacity measured by high resolution tissue respirometry on day 6 [ Time Frame: day 6 ]
    Oxidative Phosphorylation will be measured in muscle tissue using high resolution respirometry (Oroboros O2K) on day 6, after the 6 day methylpredinsolone treatment.

  3. Expression level of NFKB Inducing Kinase (NIK) in tissue measured by real time PCR on day 0 [ Time Frame: day 0 ]
    NIK expression will be measured in muscle tissue using real time PCR on day 0.

  4. Expression level of NFKB Inducing Kinase (NIK) in tissue measured by real time PCR on day 6 [ Time Frame: day 6 ]
    NIK expression will be measured in muscle tissue using real time PCR on day 6, after the 6 day methylprednisolone treatment.


Secondary Outcome Measures :
  1. Lean Body Mass as measured by Dual Energy X-Ray Absorptiometry on day 0 [ Time Frame: day 0 ]
    Lean body mass will be measured using a Hologic DEXA on day 0.

  2. Lean Body Mass as measured by Dual Energy X-Ray Absorptiometry on day 6 [ Time Frame: day 6 ]
    Lean body mass will be measured using a Hologic DEXA on day 6, after the 6 day methylprednisolone treatment.

  3. Fat Mass as measured by Dual Energy X-Ray Absorptiometry on day 0 [ Time Frame: day 0 ]
    Fat mass will be measured using a Hologic DEXA on day 0.

  4. Fat Mass as measured by Dual Energy X-Ray Absorptiometry on day 6 [ Time Frame: day 6 ]
    Fat mass will be measured using a Hologic DEXA on day 6, after the 6 day methylprednisolone treatment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   60 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Ages: 60 - 80 years.
  2. For men only: Eugonadal men, with a basal serum testosterone level for men within the normal range for the assay.
  3. For women only: women must be post-menopausal.
  4. Availability of transportation (i.e., subjects must be able to provide their own transportation to TAMU HCRF).
  5. Ability to fast for 12 hours before each of the study visits

Exclusion Criteria:

  1. Use of anticoagulant due to the risk of bleeding during the muscle biopsy procedure.
  2. Current use or history of recent use of anabolic steroids or glucocorticoids (within 3 months).
  3. Use of anti-bone-resorptive agents such as bisphosphonates, parathyroid hormone, or calcitonin.
  4. Use of live virus vaccines in the past 30 days.
  5. History of stroke.
  6. History of angina that occurs with exertion or at rest or a myocardial infarction within the last 12 months.
  7. Diagnosed systemic viral, bacterial, or fungal infections.
  8. Any established major medical illness such as chronic obstructive pulmonary disease, or untreated sleep apnea.
  9. Subjects with minor, acute inflammatory illnesses such as colds will be excluded until the acute illness has resolved.
  10. Uncontrolled endocrine or metabolic disease (e.g. liver disease, renal disease, diabetes).
  11. History or current diagnosis of type 1 or type 2 diabetes. High doses of glucocorticoids can increase insulin resistance and exacerbate diabetes.
  12. Systolic blood pressure greater than or equal to 160mm Hg or a diastolic blood pressure greater than or equal to 100mm Hg on three consecutive measurements taken at one-week intervals. Glucocorticoids can cause fluid retention that could worsen uncontrolled hypertension. Subjects will be included if they are on two or less blood pressure medications and have a blood pressure below these criteria.
  13. Subjects who engage in high intensity, elite training on a regular basis will be excluded. Additionally, subjects will be asked to refrain from any exercise during study week.
  14. History of seizure disorder.
  15. History of tuberculosis.
  16. Current diagnosis of peptic ulcer disease, gastritis, or non-ulcer dyspepsia.
  17. Current diagnosis of mental illness.
  18. Current diagnosis of cognitive impairment.
  19. Subjects with sleep disturbances.
  20. Current self-reported immunosuppressive disorder.
  21. Any other condition or event considered exclusionary by the PI and covering physician.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03529929


Locations
Layout table for location information
United States, Texas
Texas A&M University
College Station, Texas, United States, 77843
Sponsors and Collaborators
Texas A&M University
Investigators
Layout table for investigator information
Principal Investigator: Melinda Sheffield-Moore, PhD Texas A&M University
Layout table for additonal information
Responsible Party: Melinda Sheffield-Moore, Professor, Texas A&M University
ClinicalTrials.gov Identifier: NCT03529929    
Other Study ID Numbers: IRB2017-0883
First Posted: May 18, 2018    Key Record Dates
Last Update Posted: March 11, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Melinda Sheffield-Moore, Texas A&M University:
glucocorticoids
aging
NFKB
Medrol
methylprednisolone
Additional relevant MeSH terms:
Layout table for MeSH terms
Inflammation
Pathologic Processes
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Neuroprotective Agents
Protective Agents
Antineoplastic Agents, Hormonal
Antineoplastic Agents